Shuttle Pharmaceuticals
SHPH
5 hedge funds and large institutions have $87.5K invested in Shuttle Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
25% more funds holding
Funds holding: 4 → 5 (+1)
0.02% less ownership
Funds ownership: 0.04% → 0.01% (-0.02%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
71% less capital invested
Capital invested by funds: $306K → $87.5K (-$219K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$61.7K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$15.1K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$14.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$153K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$28.2K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.11K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $36.9K | +$61.7K | +380 | New |
|
|
AC
2
Armistice Capital
New York
| $27.4K | -$153K | -942 | -77% |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $13.2K | +$15.1K | +93 | +216% |
|
|
TSS
4
Two Sigma Securities
New York
| $8.63K | +$14.5K | +89 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $1.32K | -$2.11K | -13 | -48% |
|
|
FDCDDQ
6
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $25 | – | – | – |
|
7
Bank of America
Charlotte,
North Carolina
| $10 | – | – | – |
|
8
Barclays
London,
United Kingdom
| $1 | – | – | – |
|
|
9
UBS Group
Zurich,
Switzerland
| – | -$28.2K | -131 | Closed |
|
SHPH Hedge Fund Activity: Q1 2025 in Review
5 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Shuttle Pharmaceuticals (SHPH) for Q1 2025, worth a combined $87.5K — down 71% from $306K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new SHPH positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $61.7K. The largest seller was Armistice Capital, cutting an estimated $153K.
- 5 institutional investors held Shuttle Pharmaceuticals (SHPH) as of Q1 2025, up from 4 in Q4 2024.
- Funds reported $87.5K of Shuttle Pharmaceuticals stock for Q1 2025, down 71% quarter-over-quarter.
- 2 funds opened new Shuttle Pharmaceuticals positions in Q1 2025 and 1 closed out, a net change of +1 holder.
- The largest Shuttle Pharmaceuticals buyer in Q1 2025 was Citadel Advisors, an estimated $61.7K added.
- The largest Shuttle Pharmaceuticals seller in Q1 2025 was Armistice Capital, an estimated $153K sold.
Based on aggregated 13F filings for Q1 2025.